Cabozantinib
- TRADE NAMES: Carbometyx (Exelixis); Cometriq (Exelixis)
- INDICATIONS: Metastatic medullary thyroid cancer (Cometriq); advanced renal cell carcinoma (Cabometyx)
- CLASS: MET (mesenchymal-epithelial transition) inhibitor / MET tyrosine kinase inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 55 hours (Cometriq); 99 hours (Cabometyx)
FDA APPROVAL DATE: 11/30/2012 (Cometriq); 04/25/2016 (Cabometyx)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Atazanavir, Boceprevir, Carbamazepine, Clarithromycin, Conivaptan, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Nefazodone, Nelfinavir, Phenobarbital, Phenytoin, Posaconazole, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Voriconazole
PREGNANCY CATEGORY: D
PERFORATIONS AND FISTULAS, and HEMORRHAGE
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 04/05/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
